Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CASI Obtains Permission for China Phase II Cancer Trial

publication date: Nov 13, 2014
CASI Pharma, a US-China cancer drug company formerly known as EntreMed, received CFDA permission to conduct a Phase II trial of its lead molecule, ENMD-2076, in soft tissue sarcoma patients. It is the second indication in China for ENMD-2076, which was approved in July to begin a Phase II trial in patients with triple-net negative breast cancer. CASI has also filed to begin a trial of the drug in advanced ovarian clear cell carcinoma. All three are expansions of US trials. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital